Evidence map›Paper›PMID 41745734›Full record

ArticleToxins2026

Impact of Early Versus Late Treatment with Botulinum Toxin A on Goal Attainment in Post-Stroke Spasticity: A Retrospective Cohort Study.

Atul Patel, Jinming Zhang, Simon Page, Sarah Harding, Mathieu Beneteau, Colin Navickas, Alberto Esquenazi

Abstract readComparative Study
In one paragraph

Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Atul PatelKansas City Bone & Joint Clinic, Overland Park, KS 66211, USA.ORCID 0000-0003-2765-7953
Jinming ZhangIpsen, Cambridge, MA 02142, USA.ORCID 0000-0003-1621-7549
Simon PageIpsen, London W2 1AF, UK.ORCID 0000-0002-7225-3774
Sarah HardingIpsen, London W2 1AF, UK.
Mathieu BeneteauIpsen, 75015 Paris, France.ORCID 0009-0001-6741-1328
Colin NavickasGenesis Research Group, Hoboken, NJ 07030, USA.ORCID 0009-0006-2665-5998
Alberto EsquenaziJefferson Moss-Magee Rehabilitation, Elkins Park, PA 19027, USA.ORCID 0000-0003-0698-6424

Funding

Ipsen (United Kingdom) n/a
6 · The paper itself

Abstract

This study evaluated the effect of time of botulinum toxin A (BoNT-A) treatment on clinical outcomes in adults with post-stroke spasticity (PSS). Individual data were pooled from five studies. Eligible patients received ≥1 BoNT-A injection(s) for PSS and had goal attainment scaling (GAS) scores measured at baseline and 12 weeks. Patients were grouped according to time of treatment post-stroke: early (<1 year) or late (≥1 year). The primary endpoint was the total GAS (GAS-T) score change from baseline to 12 weeks. Secondary outcomes included the proportion of patients with a GAS-T score ≥ 50. Overall, 968 patients were included (166 early and 802 late). Median time post-stroke to BoNT-A treatment was 0.5 (early) versus 5.4 (late) years. Mean (standard deviation [SD]) baseline GAS scores were similar between cohorts (early: 36.9 [3.5]; late: 36.9 [3.6]). The mean (SD) change in the GAS-T score from baseline to 12 weeks was greater in the early versus late cohort (15.7 [8.9] vs. 13.1 [8.9];

Indexed as

Botulinum Toxins, Type AMuscle SpasticityNeuromuscular AgentsStrokeAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeBotulinum Toxins, Type ANeuromuscular Agentsbotulinum toxinsmuscle spasticitystroke rehabilitationtreatment outcometype A

Identifiers

PMID41745734
PMCPMC12945037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.